Vaccine treatment and control infectious than patologias utilizing heparan sulfate (hs) as cellular receptor

Abstract

Vaccine of preferential administration via mucous membranes, for the control of diseases generated by infectious agents that use heparan sulfate (HS) as a cellular receptor consisting of an immunogenic formulation for veterinary use, comprising an antigen whose cellular receptor is heparan sulfate (HS), a vehicle for oral, intranasal or parenteral administration, wherein said vehicle corresponds to D-glucosamine and functionalized N-acetyl-D-glucosamine biopolymers, with sulfur atoms, and/or functionalized chitosan biopolymer, with sulfur atoms, and where the antigen is microencapsulated by said types of functionalized biopolymers.

We claim: 
     
         1 . Immunogenic formulation for veterinary use, characterized in that it comprises:
 an antigen whose cellular receptor is heparan sulfate,   a vehicle oral, intranasal or parenteral administration,   wherein said vehicle corresponds to a biopolymer units D-glucosamine and N-acetyl-D-glucosamine functionalized sulfur atoms, and wherein the antigen is microencapsulated by said functionalized biopolymer.   
     
     
         2 . Immunogenic formulation for veterinary use, comprising:
 an antigen whose cellular receptor is heparan sulfate,   a vehicle oral, intranasal or parenteral administration,   wherein said vehicle corresponds to a biopolymer chitosan functionalized sulfur atoms, and wherein the antigen is microencapsulated by said biopolymer functionalized chitosan.   
     
     
         3 . The immunogenic formulation according to  claim 1  or  2 , wherein the biopolymer functionalized sulfur atoms comprising thiolated groups. 
     
     
         4 . The immunogenic formulation according to  claim 1  or  2 , wherein the biopolymer functionalized sulfur atoms comprising sulfated groups. 
     
     
         5 . The immunogenic formulation according to  claim 1  or  2 , wherein the functionalized biopolymer comprises thiolated sulfur atoms and sulphated groups. 
     
     
         6 . The immunogenic formulation according to  claim 1  or  2 , wherein the formulation has the following composition: 2 mL each of the formulation contains from 12 μg to 50 μg of the antigen. 
     
     
         7 . The immunogenic formulation according to  claim 1  or  2 , wherein the antigen is selected from a virus, a bacterium and a parasite. 
     
     
         8 . The immunogenic formulation according to  claim 7 , wherein the antigen is selected from a virus group consisting of PCV2, PRRSv, PPC (Classical swine fever), Equine Herpesvirus Type I (EHV-I), equine herpesvirus type IV (EHV-IV), bovine Herpesvirus type I (BoHV-I), Herpesvirus type I suino (SuHV-I) virus, bovine viral diarrhea virus, foot and mouth disease virus, porcine epidemic diarrhea (PED) virus transmissible gastroenteriris swine virus, swine vesicular disease (SVD), vesicular stomatitis virus (VSV) and viruses African swine fever (ASFV). 
     
     
         9 . The immunogenic formulation according to  claim 7 , wherein the antigen is selected from bacteria of the group consisting of:  Helycobacter  spp.,  Chlamydia  spp.,  Borrelia burgdogferi, Staphylococcus Aerus, Mycobacterium  spp.,  Listeria monocytogenes, Mycoplasma hyopneumoniae.    
     
     
         10 . The immunogenic formulation according to  claim 7 , wherein the antigen is selected from a parasite from the group consisting:  Toxoplasma gondii  and  Neospora caninum.    
     
     
         11 . The immunogenic formulation according to  claim 1  or  2 , wherein the biopolymer has a degree of deacetylation greater than 50%. 
     
     
         12 . The formulation according to  claim 1  or  2 , wherein the antigen with microparticles are functionalized biopolymer size between 1 to 20 μm and zeta potential value in the range of −30 to +30 mV. 
     
     
         13 . Use of the immunogenic formulation in animals according to  claim 1  or  2 , characterized in that serves for the preparation of a medicament useful in prevention and prophylaxis of diseases associated with viruses, bacteria and parasites as cell receptor using heparan sulfate diseases (HS). 
     
     
         14 . Use of the immunogenic formulation according to  claim 13 , wherein said medicament is a vaccine. 
     
     
         15 . Use of the immunogenic formulation according to  claim 13 , wherein said disease is selected from the group consisting virus: PCV2, PRRSv, PPC (Classical swine fever), equine herpesvirus type I (EHV-I), equine herpesvirus type IV (EHV-IV), bovine herpesvirus type I (BoHV-I), herpesvirus suino type I (SuHV-I) virus, bovine viral diarrhea virus, foot and mouth disease virus, porcine epidemic diarrhea (PED), gastroenteriris transmissible virus in pigs, swine vesicular disease (SVD), vesicular stomatitis virus (VSV) virus and African swine fever (ASFV). 
     
     
         16 . Use of the immunogenic formulation according to  claim 13 , wherein said disease is selected from the group consisting of bacteria:  Helicobacter  spp.,  Chlamydia  spp.,  Borrelia burgdogferi, Aerus Staphylococcus, Mycobacterium  spp.,  Listeria monocytogenes  and  Mycoplasma hyopneumoniae.    
     
     
         17 . Use of the immunogenic formulation according to  claim 13 , wherein said disease is selected from the group consisting of parasites:  Toxoplasma gondii  and  Neospora caninum.    
     
     
         18 . Immunogenic adjuvant formulations for veterinary use, characterized in that it comprises a biopolymer units and D-glucosamine N-acetyl-D-glucosamine functionalized sulfur atoms. 
     
     
         19 . Immunogenic adjuvant formulations for veterinary use, characterized in that it comprises a biopolymer chitosan units functionalized sulfur atoms. 
     
     
         20 . The adjuvant according to  claim 18  or  19 , wherein the biopolymer functionalized sulfur atoms comprising thiolated groups. 
     
     
         21 . The adjuvant according to  claim 18  or  19 , wherein the biopolymer functionalized sulfur atoms comprising sulfated groups. 
     
     
         22 . The adjuvant according to  claim 18  or  19 , wherein the biopolymer functionalized sulfur atoms and groups comprising thiolated sulfated. 
     
     
         23 . The adjuvant according to  claim 18  or  19 , wherein the biopolymer has a degree of greater than 50% deacetylation. 
     
     
         24 . The adjuvant according to  claim 18  or  19 , wherein the biopolymer functionalized antigen with microparticles are sized between 1 to 20 μm and zeta potential value in the range of −30 to +30 mV. 
     
     
         25 . Use of the adjuvant according to  claim 18  or  19 , characterized in that used for the preparation of a medicament useful in prevention and prophylaxis of diseases associated with viruses, bacteria and parasites as cell receptor using heparan sulfate (HS) diseases. 
     
     
         26 . Use of the adjuvant according to  claim 25 , wherein said medicament is a vaccine.